Our Portfolio

Symbiotix Biotherapies, Inc.

Symbiotix Biotherapies, Inc. is developing a novel class of molecular therapeutics based on molecules derived from the human microbiome. The company’s lead program represents the first molecule to emerge from the human microbiome, and is a first-in-class oral agent for the treatment of serious immune-mediated diseases.